Equities analysts predict that FibroGen, Inc (NASDAQ:FGEN) will post sales of $41.34 million for the current quarter, according to Zacks. Four analysts have made estimates for FibroGen’s earnings. The lowest sales estimate is $31.50 million and the highest is $48.80 million. FibroGen reported sales of $30.10 million in the same quarter last year, which indicates a positive year over year growth rate of 37.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, November 14th.

On average, analysts expect that FibroGen will report full year sales of $41.34 million for the current year, with estimates ranging from $121.40 million to $139.95 million. For the next financial year, analysts forecast that the business will post sales of $238.79 million per share, with estimates ranging from $211.00 million to $268.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for FibroGen.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The firm had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million.

A number of research firms recently weighed in on FGEN. Jefferies Group LLC reissued a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday. William Blair reissued an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Leerink Swann reissued an “outperform” rating and set a $82.00 price target (up from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. boosted their price target on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus boosted their price target on shares of FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. FibroGen presently has a consensus rating of “Buy” and an average price target of $60.17.

WARNING: “FibroGen, Inc (FGEN) Expected to Announce Quarterly Sales of $41.34 Million” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/14/fibrogen-inc-fgen-expected-to-announce-quarterly-sales-of-41-34-million-2.html.

FibroGen (NASDAQ:FGEN) opened at 51.60 on Thursday. The company has a 50-day moving average of $41.83 and a 200-day moving average of $31.58. The firm’s market cap is $3.67 billion. FibroGen has a 1-year low of $15.60 and a 1-year high of $52.50.

In other FibroGen news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $29.40, for a total value of $1,135,898.40. Following the completion of the sale, the chief executive officer now owns 3,330,780 shares of the company’s stock, valued at $97,924,932. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Pat Cotroneo sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $30.00, for a total transaction of $165,000.00. Following the completion of the sale, the vice president now directly owns 168,866 shares of the company’s stock, valued at approximately $5,065,980. The disclosure for this sale can be found here. Insiders sold 462,577 shares of company stock valued at $18,446,712 in the last ninety days. Insiders own 14.90% of the company’s stock.

Large investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. bought a new stake in FibroGen in the first quarter valued at approximately $111,000. Quantbot Technologies LP bought a new stake in FibroGen in the second quarter valued at approximately $128,000. SG Americas Securities LLC boosted its holdings in shares of FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the period. Airain ltd acquired a new position in shares of FibroGen in the first quarter valued at approximately $236,000. Finally, Amalgamated Bank acquired a new position in shares of FibroGen in the second quarter valued at approximately $237,000. 47.49% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.